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Coronary artery calcification is more prevalent in dialysis
patients than in patients without kidney disease and this is
associated with high serum phosphorus. In this study, we
evaluate the effect of calcium carbonate or sevelamer
treatments on the progression of calcification in 90
predialysis patients. Inclusion criteria were stable serum
calcium, phosphorus, parathyroid hormone, and a similar
baseline total calcium score (TCS). These patients were not
treated by phosphate binder, vitamin D, or statin. They were
given low-phosphorus diets without or with daily calcium
carbonate or sevelamer throughout the study that averaged
2 years. Baseline demographic or clinical characteristics along
with biochemical parameters were not different among the
three groups. The TCS significantly increased in patients on
the low-phosphorus diet alone, to a lesser extent in calcium
carbonate-treated patients, and not at all in sevelamer-
treated patients. The progression of coronary calcification
paralleled that of the calcium score. Our study shows that
sevelamer treatment should not be restricted to dialysis
patients; however, a larger study should be undertaken to
confirm these results.
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In patients on dialysis, the prevalence of vascular calcification
is greater than in age- and sex-matched individuals without
kidney disease;1 for instance, coronary artery calcification
(CAC) is more frequent in these patients than in individuals
with established coronary artery disease but with normal
kidney function.1,2 This finding together with the very
high rate of cardiovascular events sustains the opinion that
the presence of vascular calcification is the strongest
predictor of cardiovascular morbidity and mortality in
patients on dialysis.3 Very recently, the severity of CAC at
the time of entry in the hemodialysis has been confirmed as
an important predictor of long-term survival.4
A harmful characteristic of CACs is its progression over
the time that is regarded as further predictor of cardiac
events. Among the several pathogenetic factors contributing
to formation and progression of CAC, the serum concentra-
tion of phosphorus plays a major role.5–7 The relationship
between concentration of phosphorus, CAC, and cardiovas-
cular events is likely more complex than previously
thought.7–9 Phosphorus may accelerate the development
and progression of CAC through both passive precipitation
and cell-mediated process, the latter being more important
than the former.7 Association between higher phosphate
levels and mortality risk has been reported among pre-
dialysis patients with absolute serum phosphate levels in the
high–normal range but not among patients with lower serum
phosphate levels; it has been hypothesized that phosphorus
might contribute to mortality by increasing vascular
calcifications.8 In addition, severe CACs were found in pre-
dialysis patients despite the fact that majority of them had
concentration of serum phosphorus within the normal
range.9 Not only hyperphosphatemia but even its treatment
may promote the calcification process and enhance the
progression of CAC. The use of calcium-based phosphate
binders is, in fact, strongly associated with development and
progression of CAC due to the large amount of calcium
ingested and the consequent hypercalcemia. Thus, therapeu-
tic approaches such as limiting the use of calcium-based
phosphate binders and implementing the use of sevelamer, a
non-calcium-based phosphate binder, have been undertaken
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to modify the development or progression of CAC. Sevelamer
halted or significantly reduced the progression of CAC in
prevalent and incident patients on dialysis.2,10 However, there
is no unanimous agreement on abandoning the calcium-
based phosphate binders for the treatment of hyperpho-
sphatemia; the trials forming the case against calcium are
regarded as flawed,11 and the cost–benefit analysis indicates
that in absence of hypercalcemia, calcium acetate should
remain the treatment of choice for hyperphosphatemia in
hemodialysis patients.12
We have demonstrated that both prevalence and progres-
sion of CAC are greater in pre-dialysis patients than in
subjects with normal renal function.13 In addition, although
derangement of mineral metabolism does not predict the
prevalence of CAC, values of serum phosphorus at the upper
limit of normal range are associated with faster progression
of CAC.13,14
On the basis of the previous observations and lack of data
on phosphate binders and progression of CAC in pre-dialysis
patients, we have undertaken this study to assess the efficacy
of calcium carbonate and sevelamer in reducing the
progression of CAC in pre-dialysis patients.
RESULTS
Study design and final number of patients available for
analysis are reported in Figure 1. At the start of the study, 90
patients were randomly assigned to one of the following
regimens: low-phosphate diet alone (controls; n¼ 30), low-
phosphate dietþ calcium carbonate (n¼ 30), low-phosphate
dietþ sevelamer (n¼ 30). Six patients were lost during the
follow-up: one was assigned to low-phosphate diet suffered
acute myocardial infarction, two assigned to calcium
carbonate withdrew their consent, three assigned to sevela-
mer could not bear the cost of the drug any longer. All
dropped-out patients had baseline CAC. Thus, 84 patients
completed the study.
Baseline demographic and clinical characteristics of
patients who completed the study are reported in Table 1.
There was no statistically significant difference among the
groups apart from higher body mass index and shorter
duration of hypertension in patients assigned to sevelamer.
Baseline (initial) and end of the study (final) biochemical
variables are reported in Table 2. Initial values were not
significantly different across the groups. On the contrary,
significant changes were observed in some final values. For
instance, glomerular filtration rate and serum concentration
of calcium, alkaline phosphatase, and fibrinogen were
significantly changed in the sevelamer group. Phosphaturia
increased in controls. As expected, there was a significant
decrease in urinary phosphorus excretion with both binders
and particularly with sevelamer. Absolute mean serum
concentration of lipids did not change. However, in
sevelamer groups, median concentration of total cholesterol
decreased by 7% (from 170 to 158 mg/dl), triglycerides by
18% (from 107 to 88 mg/dl), and low-density lipoprotein
cholesterol by 11% (from 106 to 94 mg/dl); median values
remained unchanged in the other two groups.
At the end of the study, there were no statistically
significant differences in systolic, diastolic, mean blood
pressure, and pulse pressure across the groups.
Mean absolute and annualized absolute changes of total
calcium score (TCS) are reported in Figure 2 and 3. The final
TCS was significantly greater than the initial TCS in controls
(3697115 (mean7s.e.) vs 5477175; Po0.001) and in
calcium-treated subjects (340738 vs 473769; Po0.001); in
contrast, the final TCS was not significantly different from the
initial TCS among subjects receiving sevelamer (4157153 vs
4537127; NS). Annualized progression of TCS was 205782
in controls, 178740 in calcium carbonate patients, and
36732 in sevelamer patients. No significant between-group
change was found in mean absolute and annualized absolute
values of TCS.
Initial cohort of patients already screened for CAC:
Selected patients for the study according to inclusion criteria:
Patients who signed informed consent:
Available for analysis:Available for analysis:
Lost to follow-up n=1:
myocardial infarction
Lost to follow-up n=2:
informed consent withheld
Lost to follow-up n=3:
because of the cost of drug
Patients assigned
to low-P diet:
Patients assigned
to low-P diet + calcium carbonate:
Patients assigned
to low-P diet + sevelamer:
n=289
n=100
n=90
n=30 n=30 n=30
n=27n=28
Available for analysis:
n=29
Figure 1 | Study design.
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Table 1 | Baseline demographic clinical characteristics of patients
Controls (n=29) Calcium carbonate (n=28) Sevelamer (n=27)
Gender (M/F) 25/4 23/5 24/3
Age (years) 54.4 (13.7) 55.2 (12.0) 54.4 (12.9)
Body mass index (kg/m2) 24.8 (2.3) 24.5 (2.9) 26.1 (4.1)*
Traditional risk factor (n) 5.3 (1.4) 5.3 (1.2) 5.6 (1.4)
Systolic blood pressure (mm Hg) 134.4 (13.9) 136.8 (7.6) 135.5 (9.7)
Diastolic blood pressure (mm Hg) 82.2 (5.6) 84.8 (5) 80.5 (3.7)
Mean blood pressure (mm Hg) 99.4 (7.9) 102 (3.7) 98.8 (3.9)
Pulse pressure (mm Hg) 51.4 (9.7) 52.0 (10.2) 55.0 (10.7)
Duration HTN (months) 90 (89) 133 (73)* 60 (52)
Antihypertensive drugs (n) 2.1 (0.6) 2.3 (0.7) 2.5 (1.1)
Calcium channel blockers use (%) 44 48 45
Without CAC (n) 5 5 5
CAC, coronary artery calcification; F, female; HTN, hypertension; M, male.
Numbers are mean s.d.
*Po0.01 vs other groups.
Table 2 | Initial and final biochemical variables
Controls Calcium Sevelamer
Variables Initial Final Initial Final Initial Final
GFR (ml/min) 33.4 (20.2) 33.6 (25.0) 26.2 (8.3) 25.9 (5.3) 26.3 (15.6) 24.1* (14.7)
PTH (pg/ml) 140.7 (73.2) 146.9 (77.4) 172.1 (73.8) 176.1 (54.8) 136.5 (101.7) 134.9 (72.7)
Serum calcium (mg/dl) 9.2 (0.6) 9.3 (0.5) 9.0 (0.7) 9.1 (0.8) 9.2 (0.2) 9.0* (0.3)
Serum phosphorus (mg/dl) 3.9 (0.7) 3.9 (0.9) 4.6 (1.5) 4.7 (1.5) 4.5 (0.7) 4.8 (0.9)
Calcium P product (mg2dl2 ) 35.8 (7.0) 36.0 (7.8) 42.3 (8.0) 40.3 (11.8) 41.7 (6.9) 43.1 (8.4)
Alkaline phosphatase (mg/dl) 113.7 (62.2) 85.1* (25.1) 148.0 (83.2) 143.0 (93.2) 134.2 (67.1) 103.4** (47.6)
Total serum proteins (mg/dl) 7.2 (0.8) 7.5 (0.8) 6.9 (1.0) 7.2 (1.2) 7.2 (0.7) 7.2 (0.7)
Serum albumin (mg/dl) 3.9 (0.52) 4.2 (0.5) 3.8 (0.7) 3.9 (0.8) 3.9 (0.4) 4.2 (0.2)
Carbonate (mEq/l) 23.4 (3.8) 24.3 (3.5) 21.6 (5.3) 23.2 (4.2) 22.3 (3.1) 21.2 (2.3)
Homocysteine (mmol/l) 29.8 (18.7) 27.2 (14.6) 38.0 (14.5) 38.0 (14.5) 31.5 (10.5) 33.5 (19.7)
Fibrinogen (mg/dl) 342.6 (124.5) 385.5 (99.5) 401.3 (96.7) 397.3 (85.7) 424 (222) 332** (57)
Total cholesterol (mg/dl) 189.0 (36.3) 188.6 (38.8) 184.9 (32.5) 184.0 (23.5) 173.0 (50.5) 181.3 (53.1)
Triglycerides (mg/dl) 137.7 (101.8) 131.9 (94.4) 119.2 (50.3) 139.2 (50.3) 141.4 (92.3) 131.6 (109.7)
HDL cholesterol (mg/dl) 59.8 (44.1) 48.9 (13.1) 46.8 (10.2) 46.7 (10.2) 48.8 (10.7) 49.9 (11.8)
LDL cholesterol (mg/dl) 115.9 (32.1) 118.0 (47.5) 121.0 (47.4) 101.0 (33.2) 113.9 (55.1) 107.3 (39.1)
C-reactive protein (mg/dl) 0.98 (2.38) 0.34 (0.08) 1.1 (2.7) 0.33 (0.09) 0.50 (0.27) 0.73 (0.99)
Phosphorus intake (mg/day) 682 (480) 788 (470) 694 (492) 658 (478) 690 (398) 784 (385)
Phosphaturia (mg/24 h) 367 (389) 514* (285) 496 (125) 413* (126) 490 (128) 410** (130)
GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone.
Numbers are mean and s.d.
*Po0.05, **Po0.01 vs own initial.
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Figure 2 | Initial (white bars) and final (dark bars) absolute TCS in
controls (n¼ 29) and in patients assigned to calcium carbonate
(n¼ 28) and sevelamer (n¼ 27). Numbers are mean and s.e.
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Figure 3 | Annualized progression of TCS in controls (n¼ 29) and
in patients assigned to calcium carbonate (n¼ 28) and sevelamer
(n¼ 27). Numbers are mean and s.e.
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Fifteen patients without baseline CAC remained ‘not
calcified’ at the end of the study.
DISCUSSION
In a recent study, we have demonstrated progression of CAC
in pre-dialysis patients by an extent nearly similar to that
reported in patients on dialysis and in subjects with
symptomatic coronary artery disease.14 In addition, our
study has shown that higher serum concentration of
phosphorus was significantly associated to greater progres-
sion of CAC, despite that the majority of patients had normal
serum concentration of ion. Finally, fatal and not fatal cardiac
events were more frequent in patients whose CAC progressed.
These findings motivated the present study, which aimed to
evaluate whether the administration of two distinctive
phosphate binders, calcium carbonate and sevelamer, could
modify the progression of CAC in pre-dialysis patients.
Some relevant findings were attained in this study. First,
treatment with calcium carbonate in pre-dialysis patients did
not enhance the progression of CAC as it has been observed
in patients on dialysis. Second, sevelamer reduced progres-
sion of CAC in a more consistent manner than calcium
carbonate. Third, progression was observed only in patients
with CAC, whereas those without baseline CAC remained
‘non-calcified’ at the end of the study.
It is worth noting that high-risk patients were enrolled; in
fact, several traditional risk factors were associated with high
baseline calcium score. Apart from traditional risk factors,
high calcium score is regarded as a strong predictor of
cardiovascular events in patients on dialysis.4,10,15,16
Without treatment with phosphate binders CAC pro-
gressed more severely. This finding is clinically relevant. A
similar rate of progression in non-uremic individuals has
been associated with very high risk for myocardial infarc-
tion.17,18 Therefore, a potential association between progres-
sion of CAC and cardiac outcome should be taken into
account for pre-dialysis patients.
All available studies comparing the effects of sevelamer and
calcium-based phosphate binders on progression of calcifica-
tion have been undertaken in patients on dialysis with
deranged mineral metabolism. Thus, the achievement of
lower or normal serum concentration of phosphorus,
calcium, parathyroid hormone (PTH), and calcium pho-
sphorus product has been regarded as crucial determinant for
slowing down the progression of calcification. In this study,
patients without baseline alteration of mineral metabolism
were studied. Nevertheless, given that progression of CAC was
reduced only in patients treated with phosphorus binders, we
can hypothesize that serum phosphorus might have been
involved despite that its serum concentration remained within
normal range. This hypothesis seems supported by two
studies in patients not yet on dialysis. In the first study,8
increased mortality risk was not observed among people with
lower serum phosphate levels whereas an association between
phosphate and mortality risk was found among people with
serum phosphate levels in high–normal range. Serum
phosphorus of 3.5 mg/dl was associated with a significantly
increased risk for death, and mortality risk increased linearly
with each subsequent 0.5 mg/dl rise of serum phosphorus
level. Vascular calcifications were claimed as the potential
determinant of the increased mortality risk. In the second
study,9 a significant correlation was found between severe
CAC and phosphorus despite that the majority of patients had
normal serum concentration of the ion.
It is commonly recognized that development and
progression of CAC in patients on dialysis is dependent on
hyperphosphatemia on the one hand and on calcium
ingested as phosphate binder on the other hand. To our
knowledge, no clinical studies have evaluated the develop-
ment and progression of CAC in untreated and treated
patients on dialysis with calcium-based phosphate binders.
Likewise, no study has been carried out in pre-dialysis
patients. In this study, CAC progressed by a minor extent in
patients treated with calcium carbonate than in controls.
Therefore, in pre-dialysis patients, the progression of CAC
should not be unequivocally ascribed to the calcium ingested
as phosphate binder as it occurs in patients on dialysis.
Otherwise, the progression of CAC should have been greater
in patients treated with calcium carbonate than in controls,
because a significant progression has been reported in
patients on dialysis with doses of elemental calcium as small
as 1.1 g/day.10 It is likely that exogenous calcium load from
phosphate binder may have fewer effects on the calcification
process, since the function of renal tubuli is not completely
lost in CKD patients.
It is worth noting that baseline levels of serum phosphorus
and TCS were higher (although not significantly different) in
patients assigned to sevelamer than in controls; nonetheless,
sevelamer patients did not experience significant progression
of CAC and three of them had regression of the process. It has
been reported that progression is more severe when baseline
plaque burden is greater.10 The least severe progression of
CAC with sevelamer is in keeping with that found by others in
prevalent and incident patients on dialysis.2,10 Calcium scores
were, in fact, significantly lower in patients treated with
sevelamer compared to patients treated with calcium-based
phosphate binders, despite a similar control of mineral
metabolism. Fewer episodes of hypercalcemia and favorable
effects on lipid profile were potential determinants of the
greater efficacy of sevelamer in slowing down the progression
of coronary and cardiac valve calcification.2,10 In fact,
hypercalcemic episodes were less frequent in sevelamer
subjects even if an increase in serum calcium was
observed.10,19 On the contrary, in this study, a small but
significant decrease in final serum calcium (9.270.2 vs
9.070.2 mg/dl; Po0.05) was observed in patients assigned to
sevelamer; this decrease was, in our opinion, of minimal
clinical significance. In the same way, final calcium was not
increased in patients assigned to calcium carbonate. Both the
findings may be likely due to the fact that in our patients the
renal function was not completely lost and that they were not
treated with vitamin D.
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Sevelamer is the unique phosphate binder that consis-
tently decreases low-density lipoprotein cholesterol and
increases high-density lipoprotein cholesterol in patients on
dialysis.2,10,19 We cannot determine whether the greater
reduction of progression was due to the effect of sevelamer
on lipids. In fact, no significant differences were found in the
markers of lipid metabolism at the end of the study.
Nevertheless, sevelamer decreased the absolute concentration
of cholesterol and, by a greater extent, the median value of
low-density lipoprotein cholesterol; likewise, it increased
high-density lipoprotein cholesterol. More marked effects on
lipid profile observed in patients on dialysis may be due to
larger prescribed doses of sevelamer.2,10
Markers of inflammation have been associated with
mortality and coronary calcification in patients on dialysis
because they may activate arterial calcium deposition.20–22
Distinctive effects of sevelamer on inflammation are regarded
as capable of slowing down the progression of CAC.10,19 In
this study, patients assigned to sevelamer showed no changes
in the concentration of C-reactive protein and homocysteine
but showed a significant decrease in fibrinogen. In a previous
study, the markers of inflammation were not predictive
factors of either prevalence or progression of CAC in
pre-dialysis patients.13,14
Clinical studies have shown that sevelamer reduces plasma
concentration of bicarbonate, worsening metabolic acidosis
in patients on dialysis.10,12,23 In this study, the reduction of
carbonate in patients assigned to sevelamer was negligible,
likely due to, on the one hand, to a small amount of the
binder, and on the other hand, to still preserved renal
function. However, acid–base balance should be closely
monitored during treatment with higher doses of sevelamer.
The duration of hypertension was shorter in patients treated
with sevelamer than in other groups; however, this difference
had, in our opinion, no relevant implication as the duration of
hypertension was not a predictive factor of progression in
previous larger studies in pre-dialysis patients.13,14
A further relevant finding of this study is that patients
without baseline CAC remained free from CAC at the end of
the study despite similar ‘uremic’ environment and exogen-
ous promoting factors. Persisting ‘non-calcified’ patients
were, in fact, found in all groups. This finding might suggest
that use of phosphate binders is not required in pre-dialysis
patients without CAC, the progression being a natural
process that occurs only in the presence of CAC. It should
be of clinical relevance to identify demographic, biochemical,
and/or genetic characteristics that protect pre-dialysis
patients against development of CAC. The ‘non-calcified’
status is, however, not permanent; in fact, CAC has not been
found in 47% of pre-dialysis patients, in 36% of those
entering dialysis treatment, and in 11 and 7% of those on
hemodialysis for an average of 39 and 65 months,
respectively.2,3,13,16 These data may indicate that distinctive
pathogenetic factors are involved in the process leading to
development and progression of CAC among pre-dialysis
patients and those on dialysis.
LIMITATIONS
Main limitation of this study is the small number of patients.
This was mainly due to the fact that prescription of sevelamer
is authorized only for patients on dialysis.
The dosing of binders was not adjusted to reach a targeted
serum concentration of phosphorus. Nonetheless, calcium
carbonate and sevelamer were clearly effective in reducing
CAC progression.
Owing to small cohort of patients, on the one hand, and
to a large variation in the values of TCS, on the other hand,
no significant between-group change was found. No
significant between-group difference has been reported in a
recent larger study evaluating the effects of sevelamer on
progression of CAC in incident patients on dialysis.2
The exclusion of patients with diabetes might have made
the study not representative of ‘the real-life’. But patients with
diabetes would have influenced the results since diabetes
‘per se’ accelerates the progression of CAC.
CONCLUSIONS
Progression of CAC is severe in pre-dialysis patients not
treated with phosphate binders. Treatment with calcium
carbonate appears to be safe in pre-dialysis patients given
that the binder does not worsen the progression of CAC as it
does in patients on dialysis. The progression of CAC may be
more markedly hampered by sevelamer. Nevertheless, the
relatively small number of patients does not allow drawing a
definitive conclusion on both issues. Larger prospective study
should be undertaken in pre-dialysis patients to confirm
these results. In this case, the use of sevelamer should be not
restricted to patients on dialysis. Finally, it would be clinically
relevant to identify demographic, biochemical, and/or genetic
characteristics that protect some pre-dialysis patients against
the development of CAC.
MATERIALS AND METHODS
From a cohort of 289 outpatients with stage 3–5 of chronic kidney
disease not yet on dialysis and previously screened for the presence of
CAC with spiral computed tomography (CT), we selected 100
patients. Exclusion criteria were age o18 years, symptomatic
coronary disease, past myocardial infarction, previous coronary
surgery/angioplasty or stroke, progressive renal disease, and
arrhythmia (to avoid motion artifacts during CT scans). Diabetic
patients (e.g., those regularly using insulin and hypoglycemic drugs)
were excluded because progression of CAC is greater and
independent of mineral metabolism and renal function.2,24 The
inclusion criteria were constant low dietary phosphate intake; stable
serum concentration of phosphorus, calcium, calcium phosphorus
product, and PTH in the prior 6 months; no previous therapy with
aluminum- or calcium-based phosphate binders, vitamin D sterols,
and statins; comparable mean baseline TCS at CT scan.
Before the enrollment, patients were informed about the
therapeutic interventions, purpose and nature of the study, and
that the use of sevelamer in predialysis patients had not been
approved as yet by FDA or by the Health Department of our
country.
Of the initial cohort, 90 patients accepted to participate in the
study and signed written informed consent. Among these patients,
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there were some without baseline CAC (n¼ 15) to establish the
efficacy of the planned therapeutic interventions in preventing
the development of plaque.
Protocol of the study was approved by the Internal Review
Board.
Lacking references on sevelamer in predialysis patients, a pilot
study had been performed in 20 volunteers with stable stage 3–5 of
chronic kidney disease not yet on dialysis to establish the dose that
had phosphate-binding capacity and that less likely could cause
hypophosphatemia or oversuppression of PTH (data not presented).
In this pilot study, sevelamer was administered at increasing doses
from 0.8 to 2.4 g/day. The phosphate-binding capacity was evaluated
by comparing changes from baseline in urine phosphorus excretion,
measured as mean daily urine phosphorus content. The lowest dose
of binder did not affect serum concentration of phosphorus and
PTH, and did not reduce 24 h urinary phosphate excretion. On the
contrary, the highest dose reduced phosphaturia, and caused
hypophosphatemia and oversuppression of PTH in 60% of
participants.
In this study, sevelamer was administered at the daily dose of
1600 mg. The administered dose of calcium carbonate was 2 g/day,
equivalent to 1600 mg of sevelamer as counseled by the producer
when patients are shifting from calcium acetate to sevelamer.
Patients were randomly assigned to low-phosphate diet alone
and to receive either calcium carbonate or sevelamer by the co-
author (YB), who was unaware of their baseline demographic and
clinical characteristics and biochemistry.
Serum concentrations of calcium, phosphorus, PTH (i-PTH),
homocysteine, C-reactive protein, triglycerides, total cholesterol,
high-density lipoprotein cholesterol were measured; low-density
lipoprotein cholesterol was calculated using the Friedewald equa-
tion. Glomerular filtration rate was measured as 24-h measured
creatinine clearance. The biochemical measurements were obtained
at baseline and every 3 months during the observation period; the
on-treatment measurements were averaged for statistical analysis
and are reported.
Data were collected to determine in each subject the sum of
‘traditional’ risk factors such as age, gender, family history of
premature cardiovascular disease, hypertension, high total choles-
terol, low high-density lipoprotein cholesterol, hypertension,
smoking, and obesity.
CACs were assessed by multislice spiral CT (GE Medical Systems,
Milano, Italy). CT scans were performed at the entry (initial) and at
the end of the study (final). CT evaluation was carried out in an
institution external to authors’ university. Both initial and final
scans were analyzed by radiologists who were unaware of both
treatment allocation and previous CT reading.
Collection and scoring of CT images were performed as
described elsewhere.13 CT images were reconstructed with a
standard algorithm, prospective gating, 512 512 matrix, SFOV
50 cm, DFOV 25 cm. Prospective gating does not require manual
analysis and reduces variability of coronary calcium scores, being
less dependent on the operator. The system was synchronized
(Millennia 3500 CT-P) with the cardiac cycle to trigger scanning
during the R to R interval. All pixels with intensity value above the
threshold of 130 Hounsfield Units were counted; calcification was
then assigned to one of the coronary arteries. CT images were
transferred to workstation (Advantage work station; ADV 4.0), and
scored. Scores were summed to obtain the TCS.
The progression of CAC was measured both as an absolute
increase of TCS from the first to the second CT scan and as
annualized absolute change (computed as second TCSfirst TCS/
days of follow-up 365).25
The observation period lasted 2474.2 (mean7s.d.) months.
PTH was assayed by a chemiluminescent immunometric method
(Diagnostic Products Corporation, Los Angeles, CA, USA) and
hsC-reactive protein by an immunoturbidimetric method.
Variables lacking normal distribution were analyzed by
non-parametric tests. Progression of CAC was evaluated between
groups and the within group by the Kruskall–Wallis test or the
Wilcoxon signed ranks test, when appropriate. Continuous variables
were compared with Student’s t-test. Categorical variables were
compared with Fisher’s exact test.
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